PRIGNANO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.791
EU - Europa 6.368
AS - Asia 4.872
SA - Sud America 1.224
AF - Africa 182
OC - Oceania 71
Continente sconosciuto - Info sul continente non disponibili 1
Totale 21.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.663
RU - Federazione Russa 2.617
SG - Singapore 1.425
PL - Polonia 1.119
CN - Cina 1.109
BR - Brasile 998
HK - Hong Kong 883
IT - Italia 742
IE - Irlanda 607
KR - Corea 525
SE - Svezia 448
VN - Vietnam 441
DE - Germania 283
FI - Finlandia 184
IN - India 119
GB - Regno Unito 103
CI - Costa d'Avorio 97
AR - Argentina 83
JO - Giordania 80
ID - Indonesia 72
AU - Australia 68
UA - Ucraina 63
CA - Canada 58
FR - Francia 55
CH - Svizzera 43
EC - Ecuador 42
TR - Turchia 41
MX - Messico 36
CO - Colombia 33
BD - Bangladesh 31
IQ - Iraq 29
JP - Giappone 28
PY - Paraguay 24
ZA - Sudafrica 24
NL - Olanda 23
UZ - Uzbekistan 17
MA - Marocco 15
CL - Cile 14
ES - Italia 14
BE - Belgio 12
VE - Venezuela 12
EG - Egitto 10
SA - Arabia Saudita 10
KE - Kenya 9
PK - Pakistan 9
DO - Repubblica Dominicana 8
PE - Perù 8
HN - Honduras 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
AZ - Azerbaigian 6
BJ - Benin 6
IR - Iran 6
JM - Giamaica 6
LT - Lituania 6
RO - Romania 6
TN - Tunisia 6
AL - Albania 5
DK - Danimarca 5
IL - Israele 5
NP - Nepal 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
OM - Oman 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
BO - Bolivia 3
KG - Kirghizistan 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CR - Costa Rica 2
GR - Grecia 2
GT - Guatemala 2
KH - Cambogia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
PH - Filippine 2
PS - Palestinian Territory 2
PT - Portogallo 2
SM - San Marino 2
SN - Senegal 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AO - Angola 1
BF - Burkina Faso 1
BW - Botswana 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
HU - Ungheria 1
KW - Kuwait 1
Totale 21.503
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.413
Warsaw 1.113
Singapore 959
Hong Kong 738
Ashburn 727
Dublin 602
Fairfield 585
Chandler 553
Seoul 525
Buffalo 301
Hefei 299
Woodbridge 277
Lawrence 274
Altamura 272
Beijing 268
Seattle 220
Wilmington 220
Cambridge 213
Houston 211
Munich 185
Ho Chi Minh City 183
Moscow 178
Princeton 174
Los Angeles 168
Medford 148
Ann Arbor 111
Abidjan 97
The Dalles 96
San Diego 92
Jacksonville 85
São Paulo 80
Hanoi 71
Helsinki 60
Melbourne 60
Boston 59
Shanghai 59
Kent 57
Mumbai 52
Rome 47
Florence 46
Norwalk 44
New York 40
Dallas 39
Chicago 36
Bern 35
Boardman 35
Paris 33
Rio de Janeiro 33
Turku 33
Jakarta 32
Milan 32
Izmir 28
Toronto 27
Tokyo 25
London 20
Redondo Beach 20
Belo Horizonte 18
Curitiba 18
Haiphong 18
Andover 17
Bengaluru 17
Brasília 16
Biên Hòa 15
Brooklyn 15
Campinas 15
Da Nang 15
Guayaquil 15
Salt Lake City 15
Tashkent 15
Chennai 14
Hải Dương 14
Lappeenranta 14
Phoenix 14
Tianjin 14
Fortaleza 13
Hillsboro 13
Brussels 12
Frankfurt am Main 12
Guangzhou 12
Sorocaba 12
Asunción 11
Falkenstein 11
Quito 11
Baghdad 10
Bologna 10
Buenos Aires 10
Dearborn 10
Johannesburg 10
Montreal 10
Porto Alegre 10
Ribeirão Preto 10
Salvador 10
San Francisco 10
Shenzhen 10
Stockholm 10
Clifton 9
Denver 9
Niterói 9
Poplar 9
Recife 9
Totale 13.941
Salva come PNG Salva come JPEG
Nome #
Lesioni cutanee «specifiche» in corso di leucemia linfatica cronica. 543
CD30+ cutaneous T-cell lymphoma associated with sarcoidosis 318
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 313
Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy 313
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 308
SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival 294
The involvement of Smac/DIABLO, p53, NF-kB and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin 272
Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment 260
Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. 249
Efalizumab in the treatment of psoriasis: when comorbidity is an issue. 211
Prurigo nodularis and lichen simplex chronicus. 208
New and experimental treatments of vitiligo and other hypomelanoses. 205
The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. 193
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. 191
A rational approach to the treatment of vitiligo and other hypomelanoses. 181
Fibroblasts to keratinocytes redox signaling: The possible role of ROS in psoriatic plaque formation 179
Psoriasis and body mass index. 172
Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa 172
Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. 168
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 160
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 159
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 158
Circulating dendritic cell subsets in psoriatic patients before and after biologic therapy 156
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 155
Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? 151
Efalizumab-induced severe thrombocytopenia can be resolved. 150
Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. 149
A mesenchyme-derived substrate is necessary for keratinocytes differentiation but not proliferation (Abs. 148). 146
Therapeutical approaches in melasma. 145
In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy 144
Protease-activated receptor-2 downregulation is associated to vitiligo lesions 142
Unusual presentation of tuberculosis in an infliximab-treated patient--which is the correct TB screening before starting a biologic? 141
Mast cells do not play a role in vitiligo 141
Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. 136
Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis 133
Epidemiology of Psoriasis and Psoriatic Arthritis in Italy—a Systematic Review 132
Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment 131
Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. 130
The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge 129
A pediatric case of sclerodermatous graft-versus-host disease responsive to ultraviolet A1 phototherapy 129
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 129
Polygenic Score: A Tool for Evaluating the Genetic Background of Sporadic Hidradenitis Suppurativa 128
Quantity, distribution and immunophenotypical modification of dendritic cells upon biological treatments in psoriasis. 128
Reduction in psoriasis related pruritus during biologic therapy* 127
Evidence for oxidative stress in the plasma of psoriatic patients: Source of ROS and results of treatments with biologics 126
NADPH Oxidase 4 as a Source of Oxidative Stress in Fibroblasts From Patients Affected by Psoriasis 125
Intellectual Disability and Hidradenitis Suppurativa 125
Scabies: should we always perform dermatoscopy? 123
Induction of CD83+ CD14+ non-dendritic antigen-presenting cells by exposure of monocytes to IFN-alpha1 123
The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? 123
Cutaneous hyperpigmentation induced by apremilast 123
Sequential effects of photodynamic treatment of basal cell carcinoma 122
Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score 121
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 120
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 120
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 120
Morphologic and antigenic features of dendritic cells in immune-mediated dermatoses: A hypothesis of differentiation 119
Insights into the pathogenesis of HS and therapeutical approaches 119
Mental health consequences of the covid-19 pandemic long-term exposure in italian dermatologists 118
Hidradenitis suppurativa and adalimumab in the COVID-19 era 118
Source of oxidative stress in fibroblasts from patients affected by psoriasis 117
Vitiligo masks malignant acanthosis nigricans in a woman with ovarian cancer 117
High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma 117
Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis 117
Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?” 116
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study 116
What's new in malignant melanoma - treatment 115
Clinical experience with the etanercept biosimilar SB4 in psoriatic patients 115
First case of secukinumab successful therapy in a very elderly psoriatic patient 114
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 114
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study 114
Alpha-smooth muscle actin axpression by fibroblasts is not a marker of hypertrophic scars in vitro (Abs. 774). 113
Involvement of PAR-2 in vitiligo 113
Epidermal barrier reaction to an in vitro psoriatic microenvironment 113
Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis 113
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests. 112
Intermediate filament proteins of keratinocytes under different culture conditions (Abs. 244). 111
Hidradenitis suppurativa and associated diseases 111
Clinical characteristics of psoriasis in inflammatory bowel disease patients 111
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 110
Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. 107
Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin 107
Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: Correlation with clinical, dermatological, serological and genetic indices 107
Factors influencing number and differentiation of Langerhans cells within epidermis (Abs P9). 106
Effects of GM-CSF and TNF-alpha on the Langerhans cells of human epidermal sheets (Abs. 827). 106
Effect of a psoriatic microenvironment in a three-dimensional model of normal human skin 106
Clinical experience with infliximab biosimilar in psoriasis 106
Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars 106
Photodynamic therapy and apoptosis in cutaneous basal cell carcinoma (Abs 002). 104
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 104
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 104
Ultrasound detects occult entheseal involvement in early psoriatic arthritis independently of clinical features and psoriasis severity. 102
Smooth-muscle actin, desmin and prolyl 4-hydroxylase in fibroblasts grown from hypertrophic scars and keloids (Abs. 99). 100
Effects of cyclosporin-A on the morphology of human Langerhans cells in cultured epidermal sheets Abs. 7). 100
Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa 100
Atypical mycobacteria 100
Skin manifestations in psoriatic and hs patients in treatment with biologicals during the covid‐19 pandemic 100
Granulocyte macrophage-colony stimulating factor augments the functional activity of LC in vitro. 99
Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study 99
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 99
Totale 14.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.117
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021518 0 0 0 0 0 109 35 69 77 101 58 69
2021/20221.249 33 60 51 29 6 102 184 87 64 41 326 266
2022/20232.763 292 681 127 180 157 493 325 99 242 16 71 80
2023/2024924 38 81 186 43 36 65 49 215 18 76 75 42
2024/20257.588 323 897 536 982 2.135 829 210 378 490 181 278 349
2025/20265.755 946 1.325 1.030 1.223 1.106 125 0 0 0 0 0 0
Totale 21.675